Title of article :
An Investigation on the Effect of BCc1 Nanomedicine on Gastric Cancer Patients Using EORTC QLQ-STO30 Questionnaire
Author/Authors :
Hafizi ، Maryam Cancer Research Centre - Shahid Beheshti University of Medical Sciences , Kalanaky ، Somayeh Department of Research and Development - Sodour Ahrar Shargh Company , Moaiery ، Hassan Cancer Research Centre - Shahid Beheshti University of Medical Sciences , Khayamzadeh ، Maryam Cancer Research Centre - Shahid Beheshti University of Medical Sciences , Noorian ، Sajad Department of Statistics - Faculty of Sciences - University of Qom , Kaveh ، Vahid Firouzgar Hospital - Iran University of Medical Sciences , Foudazi ، Hossein Shahid Fayaz-Bakhsh Hospital , Gharib ، Behrooz Naft Company Hospital , Jenabian ، Arash Department of Medical Oncology and Hematology - Islamic Azad University, Tehran Medical Sciences Branch , Razavi ، Mohsen Firouzgar Hospital - Iran University of Medical Sciences , Salimi ، Saeid Firouzgar Hospital - Iran University of Medical Sciences , Fakharzadeh ، Saideh Department of Research and Development - Sodour Ahrar Shargh Company , Zarghi ، Afshin Department of Medicinal and Pharmaceutical Chemistry - Shahid Beheshti University of Medical Sciences , Nazaran ، Mohammad Hassan Department of Research and Development - Sodour Ahrar Shargh Company , Akbari ، Mohammad Esmaeil Cancer Research Centre - Shahid Beheshti University of Medical Sciences
Abstract :
Background: Nowadays, one criterion to assess the impact of various treatments in cancer patients is the quality of life (QOL), which represents the patients’ physical and psychosocial manner. It is already proved that BCc1 nanomedicine enjoys therapeutic behavior in cancer treatment of in vitro, animal, and human studies. Objectives: In the present study, we aimed at investigating the QOL in gastric cancer patients according to the European Organization for Research and Treatment of Cancer (EORTC QLQ-C30) questionnaire after treating them with BCc1 nanomedicine synthesized based on nanochelating technology. Methods: A randomized, double-blind, and multicenter study was conducted to investigate the QLQ-STO30 of 60 metastatic (8 weeks after treatment) and 60 non-metastatic (20 weeks after treatment) gastric cancer patients in two separate groups named BCc1 nanomedicine and placebo. Results: In the metastatic patients, the mean difference of overall QLQ-STO30 showed a 2.8-score improvement in BCc1 nanomedicine (P 0.05) and a 5.2-score decline in placebo (P 0.05); in non-metastatic patients, it showed a 2.3-score improvement in BCc1 nanomedicine (P 0.05) and a 3-score decline in placebo (P 0.05). Conclusions: The results of the study showed that BCc1 nanomedicine improves a number of indices in metastatic and nonmetastatic gastric cancer patients, such as functional domains, symptom scales, and global QOL included in EORTC QLQ-STO30 questionnaire.
Keywords :
BCc1 Nanomedicine, Quality of Life, Nanomedicine, Quality of Life , Nanomedicine , Nanochelating Technology
Journal title :
International Journal of Cancer Management
Journal title :
International Journal of Cancer Management
